Paulina Piotrowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paulina Piotrowska has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Klimczak
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
4 shared publications - Honorata Kraskiewicz
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
3 shared publications - Jolanta Lis-Kuberka
Division of Chemistry and Immunochemistry, Department of Biochemistry and Immunochemistry, Wroclaw Medical University, M. Skłodowskiej-Curie 48/50, 50-369 Wroclaw, Poland
2 shared publications - Agnieszka Krawczenko
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland
1 shared publication - Aleksandra Bielawska-Pohl
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland
1 shared publication - Aleksandra Wypychowska
Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland
1 shared publication
Latest Publications
- Open Access
Anti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification
Vascular calcification (VC) is a very common complication associated with aging, chronic kidney disease, diabetes, and atherosclerosis, predicting cardiovascular morbidity and mortality, but remains largely resistant to current therapies. This study investigated the anti-calcification properties of a secretome derived from a human adipose tissue-derived mesenchymal stem/stromal cell line (HATMSC2) using an in vitro model of vascular smooth muscle cell (VSMC) calcification. VSMCs were cultured in both inorganic and organic calcification media with or without HATMSC2 secretome supplementation (50 μg/mL). Calcium deposition was assessed with Alizarin Red S staining, while osteogenic markers (RUNX2, OPN, OSX, COL-1, OCN) and contractile marker α-SMA were evaluated with Western blot and RT-PCR. The HATMSC2 secretome significantly reduced calcium deposits and suppressed the upregulation of osteogenic markers in the organic calcification model, preventing osteogenic transdifferentiation. Furthermore, the secretome significantly decreased the adhesion of the THP-1 monocyte to VSMCs under calcification-promoting conditions, confirming its immunomodulatory effects. The detection of BMP antagonists, GREM1 and CHRDL1, MGP (anti-calcification factor), and the BMP signaling agonist BMP-7 in the HATMSC2-derived secretome indicates factors that may potentially contribute to its anti-calcification activity. These findings are consistent with the modulation of osteogenic signaling pathways; however, the precise molecular mechanisms and the individual contribution of the identified proteins require further functional validation.
Open AccessAnti-Calcification Effects of Immortalized Human Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell (HATMSC2) Secretome in an In Vitro Model of Vascular Calcification
Vascular calcification (VC) is a very common complication associated with aging, chronic kidney disease, diabetes, and atherosclerosis, predicting cardiovascular morbidity and mortality, but remains largely resistant to current therapies. This study investigated the anti-calcification properties of a secretome derived from a human adipose tissue-derived mesenchymal stem/stromal cell line (HATMSC2) using an in vitro model of vascular smooth muscle cell (VSMC) calcification. VSMCs were cultured in both inorganic and organic calcification media with or without HATMSC2 secretome supplementation (50 μg/mL). Calcium deposition was assessed with Alizarin Red S staining, while osteogenic markers (RUNX2, OPN, OSX, COL-1, OCN) and contractile marker α-SMA were evaluated with Western blot and RT-PCR. The HATMSC2 secretome significantly reduced calcium deposits and suppressed the upregulation of osteogenic markers in the organic calcification model, preventing osteogenic transdifferentiation. Furthermore, the secretome significantly decreased the adhesion of the THP-1 monocyte to VSMCs under calcification-promoting conditions, confirming its immunomodulatory effects. The detection of BMP antagonists, GREM1 and CHRDL1, MGP (anti-calcification factor), and the BMP signaling agonist BMP-7 in the HATMSC2-derived secretome indicates factors that may potentially contribute to its anti-calcification activity. These findings are consistent with the modulation of osteogenic signaling pathways; however, the precise molecular mechanisms and the individual contribution of the identified proteins require further functional validation.
- Open Access
- 19 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5566
Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Rα2—In Vitro Study
The failure of therapy in muscle invasive bladder cancer (MIBC) is primarily attributed to tumor heterogeneity and therapy resistance. We propose a novel approach targeting interleukin-13 receptor subunit alpha 2 (IL-13Rα2), which is expressed on bladder cancer (BC) cells but absent in normal urothelial cells. We investigated the therapeutic effects of WPD101a immunotoxin (IL-13-DT390) on IL-13Rα2-expressing BC cells in relation to BC cell phenotype and functional characteristics in vitro using both 2-dimensional (2D) and 3-dimensional (3D) models. Cell phenotype and IL-13Rα2 expression were assessed using flow cytometry, immunofluorescence, and Western blot analysis. The biological effects of WPD101a were evaluated by measuring cell viability and proliferation using the MTT, sulforhodamine B (SRB), CellTiter-Glo and Live/Dead assays. Apoptosis was assessed using Annexin V/propidium iodide (PI) staining, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of CASP genes expression. We found that the reference BC cell lines TCC-SUP, JMSU-1 and UM-UC-3 express IL-13Rα2 at various level in contrast to RT-4, HCV-29 and 5637 cells. Cells expressing IL-13Rα2 were sensitive to WPD101a at lower concentrations in the 2D model (0.1 ng/mL) compared to the 3D model (1.0 ng/mL). IL-13Rα2-negative cells remain resistant to the immunotoxin. WPD101a induces apoptosis in BC cells expressing IL-13Rα2 as confirmed by the presence of apoptotic cells, increase the proportion of cells in the subG1 phase, and by the effector CASP3, CASP7, and initiator CASP8, CASP9 genes expression. This study confirmed receptor-dependent cytotoxic effects of WPD101a and the ability and specificity to inhibit growth and apoptosis induction in MIBC cells expressing IL-13Rα2.
- 19 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5566
Open AccessImmunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Rα2—In Vitro Study
The failure of therapy in muscle invasive bladder cancer (MIBC) is primarily attributed to tumor heterogeneity and therapy resistance. We propose a novel approach targeting interleukin-13 receptor subunit alpha 2 (IL-13Rα2), which is expressed on bladder cancer (BC) cells but absent in normal urothelial cells. We investigated the therapeutic effects of WPD101a immunotoxin (IL-13-DT390) on IL-13Rα2-expressing BC cells in relation to BC cell phenotype and functional characteristics in vitro using both 2-dimensional (2D) and 3-dimensional (3D) models. Cell phenotype and IL-13Rα2 expression were assessed using flow cytometry, immunofluorescence, and Western blot analysis. The biological effects of WPD101a were evaluated by measuring cell viability and proliferation using the MTT, sulforhodamine B (SRB), CellTiter-Glo and Live/Dead assays. Apoptosis was assessed using Annexin V/propidium iodide (PI) staining, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of CASP genes expression. We found that the reference BC cell lines TCC-SUP, JMSU-1 and UM-UC-3 express IL-13Rα2 at various level in contrast to RT-4, HCV-29 and 5637 cells. Cells expressing IL-13Rα2 were sensitive to WPD101a at lower concentrations in the 2D model (0.1 ng/mL) compared to the 3D model (1.0 ng/mL). IL-13Rα2-negative cells remain resistant to the immunotoxin. WPD101a induces apoptosis in BC cells expressing IL-13Rα2 as confirmed by the presence of apoptotic cells, increase the proportion of cells in the subG1 phase, and by the effector CASP3, CASP7, and initiator CASP8, CASP9 genes expression. This study confirmed receptor-dependent cytotoxic effects of WPD101a and the ability and specificity to inhibit growth and apoptosis induction in MIBC cells expressing IL-13Rα2.
- Open Access
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
Prevention of Vascular Calcification via Fetuin-Modified Bioprosthetic Implants: Insights from in Vitro Models
Research into bioprosthetic heart valve (BHV) materials seeks to enhance durability and biocompatibility, particularly by mitigating vascular calcification (VC). VC entails hydroxyapatite deposition in blood vessel walls through vascular smooth muscle cells (VSMCs) phenotypic switching to osteogenic differentiation, driven by pro-calcific signals that might be inhibited by fetuin-A. To our knowledge, no prior studies have reported fetuin-coated bovine vein tissue for this purpose. This study aimed to evaluate the cytotoxicity, biocompatibility, and anti-calcification potential of fetuin-coated biomaterial. The effectiveness of fetuin coating on biomaterial was characterized using photoluminescence (PL), FTIR and Raman spectroscopy, while fetuin release was quantified. Biocompatibility was evaluated in vitro on VSMCs and human iliac artery endothelial cells (HIAE-78T) and in vivo by subcutaneous implantation in Wistar rats. The effects of fetuin were investigated in two in vitro calcification models based on 2 mM inorganic phosphate, or 10 mM β-glycerophosphate in an organic model. The induction of osteogenic markers such as osterix, bone morphogenic protein 2, and collagen type 1, osteocalcin and osteopontin, was assessed at both the mRNA and protein levels. Detoxification of glutaraldehyde-fixed biomaterial using glycine and NaBH₄ eliminated cytotoxicity, markedly enhancing biocompatibility toward VSMCs, HIAE-78T and subcutaneous rat implants, which showed no acute rejection and preserved structural integrity. Fetuin coating, with ~30% sustained release over three weeks, significantly inhibited mineralization on non-cellular and organic VSMCs models by decreasing mineral deposition, osteogenic markers expression. These results position fetuin-coated bovine vein biomaterial as a novel, promising anti-calcification strategy enhancing long-term durability and cardiac valves safety.
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrevention of Vascular Calcification via Fetuin-Modified Bioprosthetic Implants: Insights from in Vitro Models
Research into bioprosthetic heart valve (BHV) materials seeks to enhance durability and biocompatibility, particularly by mitigating vascular calcification (VC). VC entails hydroxyapatite deposition in blood vessel walls through vascular smooth muscle cells (VSMCs) phenotypic switching to osteogenic differentiation, driven by pro-calcific signals that might be inhibited by fetuin-A. To our knowledge, no prior studies have reported fetuin-coated bovine vein tissue for this purpose. This study aimed to evaluate the cytotoxicity, biocompatibility, and anti-calcification potential of fetuin-coated biomaterial. The effectiveness of fetuin coating on biomaterial was characterized using photoluminescence (PL), FTIR and Raman spectroscopy, while fetuin release was quantified. Biocompatibility was evaluated in vitro on VSMCs and human iliac artery endothelial cells (HIAE-78T) and in vivo by subcutaneous implantation in Wistar rats. The effects of fetuin were investigated in two in vitro calcification models based on 2 mM inorganic phosphate, or 10 mM β-glycerophosphate in an organic model. The induction of osteogenic markers such as osterix, bone morphogenic protein 2, and collagen type 1, osteocalcin and osteopontin, was assessed at both the mRNA and protein levels. Detoxification of glutaraldehyde-fixed biomaterial using glycine and NaBH₄ eliminated cytotoxicity, markedly enhancing biocompatibility toward VSMCs, HIAE-78T and subcutaneous rat implants, which showed no acute rejection and preserved structural integrity. Fetuin coating, with ~30% sustained release over three weeks, significantly inhibited mineralization on non-cellular and organic VSMCs models by decreasing mineral deposition, osteogenic markers expression. These results position fetuin-coated bovine vein biomaterial as a novel, promising anti-calcification strategy enhancing long-term durability and cardiac valves safety.
- Open Access
- 24 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 209
Mesenchymal Stem Cell Secretome for Cardiac Regeneration: Opportunity for Cell-Free Therapy
Cell-free therapy is gaining increasing interest among researchers as an alternative to mesenchymal stem/stromal cell (MSC) therapy. Since the therapeutic effects of MSCs rely predominantly on their paracrine activity, the use of their secretome as a therapeutic agent in broadly defined regenerative medicine, including cardiac regeneration, appears to be a rational approach. In this review, we discuss recent studies that employed secretomes derived from various types of MSCs in cardiomyocyte regeneration following myocardial infarction (MI). Special attention is given to the protein components of the secretome, which may drive tissue repair, and methods of priming the MSC to achieve secretome composition tailored for heart regeneration. Finally, we summarize recent preclinical findings on the effects of MSC secretomes on cardiomyocyte regeneration.
- 24 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 209
Open AccessMesenchymal Stem Cell Secretome for Cardiac Regeneration: Opportunity for Cell-Free Therapy
Cell-free therapy is gaining increasing interest among researchers as an alternative to mesenchymal stem/stromal cell (MSC) therapy. Since the therapeutic effects of MSCs rely predominantly on their paracrine activity, the use of their secretome as a therapeutic agent in broadly defined regenerative medicine, including cardiac regeneration, appears to be a rational approach. In this review, we discuss recent studies that employed secretomes derived from various types of MSCs in cardiomyocyte regeneration following myocardial infarction (MI). Special attention is given to the protein components of the secretome, which may drive tissue repair, and methods of priming the MSC to achieve secretome composition tailored for heart regeneration. Finally, we summarize recent preclinical findings on the effects of MSC secretomes on cardiomyocyte regeneration.